Pyelonephritis cost-effectiveness of therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Bot: Removing from Primary care)
 
(7 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Pyelonephritis}}
{{Pyelonephritis}}
 
{{CMG}}{{AE}}{{USAMA}}
==Overview==
==Overview==
According to an estimate the mean cost of diagnosing and managing a patient with [[urinary tract infection]] including pyelonephritis is more than 229 pounds per year. [[Hyaluronan]] therapy given long term cuts down the cost of multiple pretreatments as it prevents recurrence of a [[Urinary tract infection]].<ref name="pmid23921624">{{cite journal| author=Riedl C, Engelhardt P, Schwarz B| title=Treatment costs of bladder pain syndrome/interstitial cystitis in Austria: a pharmacoeconomic approach following current guidelines. | journal=Clin Drug Investig | year= 2013 | volume= 33 | issue= 10 | pages= 737-42 | pmid=23921624 | doi=10.1007/s40261-013-0119-4 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23921624  }} </ref><ref name="pmid23475540">{{cite journal| author=Ciani O, Grassi D, Tarricone R| title=An economic perspective on urinary tract infection: the "costs of resignation". | journal=Clin Drug Investig | year= 2013 | volume= 33 | issue= 4 | pages= 255-61 | pmid=23475540 | doi=10.1007/s40261-013-0069-x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23475540  }} </ref>
According to an estimate the mean cost of diagnosing and managing a patient with [[urinary tract infection]] including pyelonephritis is more than 229 pounds per year. [[Hyaluronan]] therapy given long term cuts down the cost of multiple pretreatments as it prevents recurrence of a [[urinary tract infection]].<ref name="pmid23921624">{{cite journal| author=Riedl C, Engelhardt P, Schwarz B| title=Treatment costs of bladder pain syndrome/interstitial cystitis in Austria: a pharmacoeconomic approach following current guidelines. | journal=Clin Drug Investig | year= 2013 | volume= 33 | issue= 10 | pages= 737-42 | pmid=23921624 | doi=10.1007/s40261-013-0119-4 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23921624  }} </ref><ref name="pmid23475540">{{cite journal| author=Ciani O, Grassi D, Tarricone R| title=An economic perspective on urinary tract infection: the "costs of resignation". | journal=Clin Drug Investig | year= 2013 | volume= 33 | issue= 4 | pages= 255-61 | pmid=23475540 | doi=10.1007/s40261-013-0069-x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23475540  }} </ref>


==Cost-effective therapies==
==Cost Effectiveness of therapies==
*[[Hyaluronan]] is very cost effective in the long run when compared with all alternative treatments, despite initial high costs.<ref name="pmid23921624">{{cite journal| author=Riedl C, Engelhardt P, Schwarz B| title=Treatment costs of bladder pain syndrome/interstitial cystitis in Austria: a pharmacoeconomic approach following current guidelines. | journal=Clin Drug Investig | year= 2013 | volume= 33 | issue= 10 | pages= 737-42 | pmid=23921624 | doi=10.1007/s40261-013-0119-4 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23921624  }} </ref>
*[[Amoxicillin]] is almost two times cheaper than [[aminoglycosides]] when used in the treatment of uncomplicated [[cystitis]] and [[pyelonephritis]].<ref name="pmid23475540">{{cite journal| author=Ciani O, Grassi D, Tarricone R| title=An economic perspective on urinary tract infection: the "costs of resignation". | journal=Clin Drug Investig | year= 2013 | volume= 33 | issue= 4 | pages= 255-61 | pmid=23475540 | doi=10.1007/s40261-013-0069-x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23475540  }} </ref>
*First and Second generation [[cephalosporins]] are considered to be cost effective in treating lower urinary tract infections empirically.<ref name="pmid10911441">{{cite journal| author=Jakobi P, Goldstick O, Finkelstein R, Itzkovitz-Eldor J| title=[Empirical treatment of urinary tract infections in the delivery room--findings and desires]. | journal=Harefuah | year= 1998 | volume= 135 | issue= 9 | pages= 344-7, 408 | pmid=10911441 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10911441  }} </ref>
*[[Gentamicin]] is suggested as an cost effective therapy for treatment of pyelonephritis during pregnancy.<ref name="pmid10911441">{{cite journal| author=Jakobi P, Goldstick O, Finkelstein R, Itzkovitz-Eldor J| title=[Empirical treatment of urinary tract infections in the delivery room--findings and desires]. | journal=Harefuah | year= 1998 | volume= 135 | issue= 9 | pages= 344-7, 408 | pmid=10911441 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10911441  }} </ref>
*The use of [[fluoroquinolone]] and [[nitrofurantoin]] is not cost effective.<ref name="pmid11784218">{{cite journal| author=Huang ES, Stafford RS| title=National patterns in the treatment of urinary tract infections in women by ambulatory care physicians. | journal=Arch Intern Med | year= 2002 | volume= 162 | issue= 1 | pages= 41-7 | pmid=11784218 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11784218  }} </ref>


==References==
==References==
Line 12: Line 17:
{{WH}}
{{WH}}
{{WS}}
{{WS}}
[[Category:Emergency mdicine]]
[[Category:Disease]]
[[Category:Up-To-Date]]
[[Category:Infectious disease]]
[[Category:Neurology]]

Latest revision as of 23:54, 29 July 2020

Urinary Tract Infections Main Page

Pyelonephritis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pyelonephritis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocaridogram

X Ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pyelonephritis cost-effectiveness of therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pyelonephritis cost-effectiveness of therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pyelonephritis cost-effectiveness of therapy

CDC on Pyelonephritis cost-effectiveness of therapy

Pyelonephritis cost-effectiveness of therapy in the news

Blogs on Pyelonephritis cost-effectiveness of therapy

Directions to Hospitals Treating Pyelonephritis

Risk calculators and risk factors for Pyelonephritis cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Usama Talib, BSc, MD [2]

Overview

According to an estimate the mean cost of diagnosing and managing a patient with urinary tract infection including pyelonephritis is more than 229 pounds per year. Hyaluronan therapy given long term cuts down the cost of multiple pretreatments as it prevents recurrence of a urinary tract infection.[1][2]

Cost Effectiveness of therapies

References

  1. 1.0 1.1 Riedl C, Engelhardt P, Schwarz B (2013). "Treatment costs of bladder pain syndrome/interstitial cystitis in Austria: a pharmacoeconomic approach following current guidelines". Clin Drug Investig. 33 (10): 737–42. doi:10.1007/s40261-013-0119-4. PMID 23921624.
  2. 2.0 2.1 Ciani O, Grassi D, Tarricone R (2013). "An economic perspective on urinary tract infection: the "costs of resignation"". Clin Drug Investig. 33 (4): 255–61. doi:10.1007/s40261-013-0069-x. PMID 23475540.
  3. 3.0 3.1 Jakobi P, Goldstick O, Finkelstein R, Itzkovitz-Eldor J (1998). "[Empirical treatment of urinary tract infections in the delivery room--findings and desires]". Harefuah. 135 (9): 344–7, 408. PMID 10911441.
  4. Huang ES, Stafford RS (2002). "National patterns in the treatment of urinary tract infections in women by ambulatory care physicians". Arch Intern Med. 162 (1): 41–7. PMID 11784218.

Template:WH Template:WS